Summary: The University of Bath-led GlucoBrain project has secured £500,000 to develop a pioneering multi-organ “organ-on-chip” biochip that physically connects living human tissue models of the gut, pancreas and brain. This three-year pilot study will track real-time molecular signals and cellular responses to changing glucose and hormone levels to investigate how diabetes increases the risk of cognitive decline, learning difficulties and Alzheimer’s disease.
GlucoBrain aims to reveal the cellular and molecular pathways that carry metabolic disturbances from the gut and pancreas to the brain. By recreating a fluidically linked, three-dimensional microenvironment where human cells communicate as they would in the body, the platform will let researchers observe how glucose, insulin and other hormones influence neural function and how candidate drugs affect those interactions.
Key Facts
- The connected biochip: GlucoBrain is a first-of-its-kind multi-organ microfluidic system designed to replicate the dynamic communication between gut, pancreas and brain tissue using living human cells.
- Beyond flat cultures: Unlike traditional two-dimensional cell cultures, organ-on-chip devices support three-dimensional tissue architecture, controlled nutrient flow and realistic cell–cell signaling, producing more physiologically relevant data.
- Decoupling the diabetes–dementia link: Clinical evidence connects diabetes to cognitive impairment, but existing models struggle to isolate the direct biochemical routes between metabolic organs and the brain. The GlucoBrain platform enables isolation and monitoring of individual cell types to map that cross-talk in real time.
- Phased development: The team will first construct separate gut, pancreas and brain modules, then integrate them into a single, fluidically connected circuit, progressively adding complexity while testing responses to glucose, hormones and drugs.
- Clinical and translational potential: Validating drug responses on human cells can accelerate drug discovery, reduce dependence on animal models, and support future personalized medicine approaches using patient-derived cells.
Funding and collaboration
The three-year pilot project begins in October and is funded by the Engineering and Physical Sciences Research Council (EPSRC) Health Technologies Connectivity Awards. The study is led by experts in Lab-on-Chip research at the University of Bath, with clinical and disease-specialist collaboration from the University of Oxford (diabetes and metabolic disease expertise) and Johns Hopkins University (Alzheimer’s disease and brain organoid expertise).
Why this matters
Diabetes and Alzheimer’s disease are major global health challenges, particularly in ageing populations. While diabetes is well known to harm the heart, kidneys and eyes, mounting clinical data also associate metabolic dysfunction with problems in memory, learning and cognition. The precise biological mechanisms that translate metabolic imbalance into altered brain function remain unclear. GlucoBrain offers a controlled, human-cell-based environment to observe those mechanisms directly at the cellular and molecular levels.
Dr Despina Moschou, project lead, explains: “Our gut, pancreas and brain constantly exchange hormonal and metabolic signals to regulate hunger and blood sugar. By recreating that communication on a connected chip, we can observe in real time how signals travel between organs, how diabetes may impair brain function, and how new therapies might restore healthy interactions.”
Research approach
An interdisciplinary team of engineers, clinicians, biologists and computer scientists will build and validate the platform. The initial phase focuses on engineering robust, physiologically accurate individual modules for each organ model. Subsequent phases connect these modules into a multi-organ circuit, increasing biological complexity and testing responses to glucose fluctuations, hormonal signals and drug candidates. Artificial intelligence and advanced data analysis will support interpretation of complex, time-resolved signaling patterns.
Long-term goals
GlucoBrain is an early-stage pilot intended to establish methods and demonstrate feasibility. If successful, the approach could expand to include additional organs and cell types, enhance drug-screening pipelines, reduce animal testing, and ultimately enable personalized testing using a patient’s own cells to predict individual responses to therapies.
Key Questions Answered:
A: The gut, pancreas and brain communicate continuously through hormonal and metabolic signals that regulate hunger, insulin and blood sugar. Chronic disruption of this signaling—such as in diabetes—appears to affect brain regions responsible for memory and learning. GlucoBrain is designed to show how metabolic disturbances propagate from digestive organs to neural tissue at the molecular level.
A: While animal models are valuable for whole-organism studies, species differences in cellular biology and signaling can limit translational accuracy. Organ-on-chip devices use human cells in physiologically relevant microenvironments, producing data that better reflect human biology and reducing uncertainties caused by interspecies differences.
A: In the future, clinicians could use a patient’s stem cells to create personalized multi-organ biochips. Testing medications on that personalized model would reveal which treatments are most effective for an individual’s biology, improving treatment selection and reducing trial-and-error prescribing.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by staff.
About this neurotech and dementia research news
Author: Sarah Baker-Gaunt
Source: University of Bath
Contact: Sarah Baker-Gaunt – University of Bath
Image: The image is credited to Neuroscience News